Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibodies binding rankl and uses thereof

A monoclonal antibody, antigen technology, applied in the direction of antibodies, antibody medical components, medical preparations containing active ingredients, etc., can solve problems such as infection

Pending Publication Date: 2022-07-29
BIOSION INC
View PDF55 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Despite the positive benefit-risk ratio and favorable therapeutic effect of denosumab, adverse effects such as pain, anemia, diarrhea, and skin problems, and in some cases serious infections, were observed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies binding rankl and uses thereof
  • Antibodies binding rankl and uses thereof
  • Antibodies binding rankl and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0126] Preparation of monoclonal antibodies of the present application

[0127] The monoclonal antibodies (mAbs) of the present application can be prepared using the somatic hybridization (hybridoma) technique known in the art of Kohler and Milstein (1975) Nature 256:495. Other embodiments of making monoclonal antibodies include viral or oncogenic transformation of B lymphocytes and phage display techniques. Chimeric or humanized antibodies are well known in the art. See, eg, US Patents 4,816,567; 5,225,539; 5,530,101; 5,585,089; 5,693,762; and 6,180,370, the contents of which are incorporated herein by reference in their entirety.

[0128] Generation of transfectomas producing monoclonal antibodies of the present application

[0129]Antibodies of the present application can also be produced in host cell transfectomas using, for example, a combination of recombinant DNA techniques and gene transfection methods well known in the art (eg, Morrison, S. (1985) Science 229:12...

Embodiment 1

[0166] Example 1. Generation of mouse-derived RANKL monoclonal antibody using hybridoma technology

[0167] immunity

[0168] Mice were immunized according to the method described in E Harlow, D. Lane, Antibody: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998. Recombinant human RANKL protein (amino acid sequence 136-317, uniprot #014788) was prepared in-house with human IgG1 Fc at the C-terminus as an immunogen, also for determination of antiserum titers and screening of hybridomas secreting antigen-specific antibodies.

[0169] The immunization dose contained 25 μg human RANKL-Fc protein / mouse / injection for primary and booster immunizations. To increase the immune response, Freund's complete adjuvant and Freund's incomplete adjuvant (Sigma, St. Louis, Mo., USA) were used in primary and booster immunizations, respectively. Briefly, adjuvant-antigen mixtures were prepared as follows. First, mix the adjuvant in the vial using a vorte...

Embodiment 2

[0172] Example 2. Affinity determination of mouse RANKL monoclonal antibody using Octet biofilm interferometry

[0173]The purified RANKL mouse-derived monoclonal antibody produced in Example 1 was characterized for affinity and binding kinetics using the Octet system (ForteBio, Octet RED 96).

[0174] Briefly, AHC / AMC biosensors (anti-human / anti-mouse IgG Fc capture, ForteBio) were pre-soaked in 10 mM glycine (pH 1.5) for 3 sec before immersion in flow buffer containing 0.5% w / v BSA in the wells of PBST) for 3 seconds and the above soaking and immersion steps were repeated three times. After immersing the sensor in HBS-EP containing + 5.0 μg / mL of the RANKL antibody of the present application or the control reference (denosumab, prepared with the heavy and light chains of amino acid sequences of SEQ ID NOs: 38 and 39, respectively) in the wells for 100 seconds, followed by immersion in HBS containing -EP + hole for 5 minutes. in another containing HBS-EP + 180 seconds ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an isolated monoclonal antibody or an antigen binding part thereof, which specifically binds to human RANKL. Nucleic acid molecules encoding the antibodies or antigen-binding portions thereof, expression vectors, host cells and methods of expressing the antibodies or antigen-binding portions thereof are also provided. The present application also provides methods of treatment using the RANKL antibody or antigen-binding portion thereof.

Description

[0001] RELATED APPLICATIONS AND INCORPORATED BY REFERENCE [0002] This application claims priority to US Provisional Patent Application US 62 / 947,541, filed on December 13, 2019. [0003] The above application, all documents cited in the above application or cited during the prosecution of the above application ("application citation documents"), all documents cited or referred to in this application (including but not limited to all documents, patents, Published patent applications) ("this application citations"), all documents cited or referred to in this application citation, and manufacturer's manuals, instructions, Product Specifications and Product Pages, are incorporated herein by reference and may be employed in practicing the present invention. More specifically, all references are incorporated herein by reference as if each document were specifically and individually incorporated by reference. Any Genbank sequences mentioned in this application are incorporated here...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/00A61P7/06C12N5/20C12N15/09C07K16/28C07K16/44A61K39/00A61K39/395
CPCA61P7/06C07K16/2875C07K2317/92C07K2317/76C07K2317/24C07K2317/94A61P35/00A61K39/3955A61K45/06C07K2317/565
Inventor 陈明久仲晓燕夏树开
Owner BIOSION INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com